Corium, Lotus Pharmaceutical seal deal for Alzheimer’s drug ADLARITY in Asia
Corium, a biopharmaceutical frontrunner in the neuroscience arena, and Lotus Pharmaceutical, a global pharmaceutical powerhouse, have declared a collaboration and license agreement. This pact centers around ADLARITY (donepezil transdermal system), an unprecedented Alzheimer’s dementia therapy, targeting ten key Asian markets.
ADLARITY, hailed as the U.S. Food and Drug Administration’s first-ever once-weekly patch to address mild to severe Alzheimer’s-type dementia, brings forth a unique method of treatment. Leveraging Corium’s proprietary Corplex technology, ADLARITY ensures a continuous release of donepezil via the skin, sidestepping the gastrointestinal tract. This leads to a remarkably improved side effect profile. It’s worth noting that donepezil, the main component in oral medication Aricept, stands out as the principal Alzheimer’s dementia treatment within the acetylcholinesterase class globally. The duo is gearing up for regulatory approval submissions across certain Asian locales later in the year.
Expressing his enthusiasm, Perry Sternberg, the helm of Corium, remarked, “Partnering with Lotus amplifies our shared passion for ADLARITY’s innovative donepezil delivery system. This tie-up paves the way for ADLARITY’s global brand ascendancy and reinforces Corium’s commitment to groundbreaking treatments benefiting patients, their kin, and caregivers.”
Echoing Sternberg’s sentiment, Lotus Pharmaceutical CEO, Petar Vazharov, stated, “This collaboration emphasizes our relentless pursuit of innovative solutions for Asia’s medical voids and underscores our dynamic growth trajectory. With ADLARITY in our arsenal, we’re poised to revolutionize Alzheimer’s care across our markets, further establishing our commanding presence in CNS.”
The agreement’s specifics grant Lotus Pharmaceutical the exclusive distribution rights for ADLARITY, spanning countries such as Taiwan, South Korea, Singapore, and seven others. Lotus Pharmaceutical will spearhead the regulatory approval process, while Corium pledges to deliver the finished product. Financially, Corium is set to receive an initial payment, complemented by milestone payments contingent on product sales performance.